On Track to Profitability, Price Target Increased (MST), page-4

First 4 Last

Share
Profile

Follow
stonks92

4,822 Posts.

509

02/09/24

10:50

Post #: 75484317
Share

Originally posted by TheAnalyst007: ↑

Research report by MST out this morning.

They have increased their price target on the back of stronger than expected results. They forecast continued strong growth and near term profitability as early as the current financial year (for the Glaucoma division at least). The price target of 48c is a bit conservative in my view, I know E&P Financial is targeting 60c per share, but it would certainly be a good starting point to getting this company's valuation closer to the fair value.

They also believe that the group is "fully funded", which is a view I also share. I think people underestimate the operating leverage here, you only need to look at the recent result and compare H2 to H1 to see the enormous improvement in the bottom line simply as a result of a bit more scale. If the growth trend continues (which I can't imagine it won't), this company will be printing cash in no time. The device practically sells itself, and the gross margins are enormous. This is not to say I don't think they will ever again do a cap raise, they may indeed take the opportunity to raise some additional cash to speed up the global expansion if the price is right (perhaps if it suddenly were to rally to $1), but it doesn't seem like they need any more cash to simply keep the lights on. iTrack Advance can take care of that. Those who are waiting for one may be waiting for a while, or for a much higher price!

Full report here: MST Access

Expand

Your pumping isn’t working 007

EYE Price at posting: 21.0¢ Sentiment: Sell Disclosure: Not Held
2 Upvote

0 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 302 more messages in this thread...

First 4 Last

Add EYE (ASX) to my watchlist

(20min delay)
Last 19.0¢		Change 0.010(5.56%)		Mkt cap ! $43.52M

Open	High	Low	Value	Volume
18.5¢	19.0¢	18.5¢	$30.04K	160K

Buyers (Bids)

No.	Vol.	Price($)
2	130000	18.5¢

Sellers (Offers)

Price($)	Vol.	No.
19.0¢	22668	3

View Market Depth

No.	Vol.	Price($)
2	130000	0.185
1	80000	0.180
3	120000	0.175
4	73000	0.170
4	114241	0.165

Price($)	Vol.	No.
0.190	22668	3
0.195	108370	2
0.200	123323	3
0.205	15050	1
0.215	204291	4

Last trade - 11.52am 07/10/2024 (20 minute delay)

EYE (ASX) Chart

On Track to Profitability, Price Target Increased (MST), page-4

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

On Track to Profitability, Price Target Increased (MST), page-4

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News